帕金森病新纪元:Solengepras引领超越多巴胺的治疗转型
A New Era in Parkinson’s: Solengepras Leads the Shift Beyond Dopamine
生物技术与制药领域的最新动态
A New Era in Parkinson’s: Solengepras Leads the Shift Beyond Dopamine
Bristol Myers expands Breyanzi approval to marginal zone lymphoma
Thermo Fisher Scientific expands bioprocessing capabilities in India, Korea and Singapore - chemengonline.com
Other news to note for Dec. 5, 2025
Regulatory actions for Dec. 5, 2025
Money raised by biopharma
Biopharma money raised: Jan. 1-Dec. 4, 2025
BioWorld and Nasdaq stock indices
ACIP drops universal hepatitis B birth dose recommendation
NICE adds further details on how the UK will pay more for drugs
Biopharma money raised by quarter in 2025 (US$M)
Denali drug hold; Intercept layoffs; Capital raises for Immatics, Capricor and Protara
Rapport shares updated results from Phase 2 study of seizure drug
Autoantibody-triggered podocyte membrane budding drives autoimmune kidney disease
Renal PIEZO2 is an essential regulator of renin
A fin-loop-like structure in GPX4 underlies neuroprotection from ferroptosis
Chutes & Ladders—Yet another CDER leadership shake-up
Praxis claims efficacy success in phase 2 seizure trial, setting up approval talks with FDA
Cancer blood test developer Freenome to go public in $330M SPAC deal
Biopharma sentiment hit a turning point in October